Human neurophysins in carcinoma of the lung: relation to histology, disease stage, response rate, survival, and syndrome of inappropriate antidiuretic hormone secretion.
At diagnosis, 65% of 103 patients with small cell carcinoma of the lung were found to have elevated plasma concentrations of vasopressin-associated human neurophysin (VP-HNP), oxytocin-associated human neurophysin (OT-HNP), or both, which were thought to be related to tumor secretion of these proteins. The remainder of patients were designated as nonsecretors (24%) or possible secretors (11%), depending upon plasma concentration of the neurophysins prior to therapy. There was a significantly higher percentage of secretors among patients with extensive disease (82%) than among those with limited disease (40%) (P = 0.001). However, within each stage group, there was no correlation between secretory status and response to therapy, survival, or histologic subtype. In addition, patients who initially were nonsecretors or possible secretors maintained this status throughout the course of disease remission and subsequent relapse. These findings suggest the possibility of biochemical differences between tumors which present as limited disease and those which present as extensive disease. The syndrome of inappropriate antidiuretic hormone secretion (SIADH) was infrequent in limited disease but was present in 33% of patients with extensive disease. SIADH was not seen without VP-HNP elevation; however, with extensive disease, 49% of patients with elevated VP-HNP had SIADH. In contrast, elevated plasma concentrations of the neurophysins were seen in only 19.6% of 56 patients with non-small cell carcinoma of the lung. The levels were in general lower than those in patients with small cell carcinoma and were seen at approximately equal frequencies in each major cellular subtype.
D000230:Adenocarcinoma / Q000150:complications / Q000378:metabolism* / Q000401:mortality; D018288:Carcinoma, Small Cell / Q000150:complications / Q000378:metabolism* / Q000401:mortality; D002294:Carcinoma, Squamous Cell / Q000150:complications / Q000378:metabolism* / Q000401:mortality; D006801:Humans; D007177:Inappropriate ADH Syndrome / Q000150:complications; D008175:Lung Neoplasms / Q000150:complications / Q000378:metabolism* / Q000401:mortality; D009481:Neurophysins / Q000378:metabolism*; D010121:Oxytocin / Q000378:metabolism; D011379:Prognosis; D014667:Vasopressins / Q000378:metabolism
D009481:Neurophysins; D014667:Vasopressins; D010121:Oxytocin